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The social value of an innovation is comprised of the value to consumers and the value to innovators.
We estimate that for the HIV/AIDS therapies that entered the market from the late 1980's onwards,
innovators appropriated only 5% of the social surplus arising from these new technologies. Despite
the high annual costs of these drugs to patients, the low share of social surplus going to innovators
raises concerns about advocating cost-effectiveness criteria that would further reduce this share, and
hence further reduce incentives for innovation.
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The  value  of  a  new  technology  may  be  divided  between  consumers,  whose 
willingness to pay may exceed the price paid, and producers or innovators, whose 
costs may be lower than the price charged.  Consumer surplus is central to static 
efficiency after an innovation has been discovered, while producer surplus, which 
forms the incentive for firms to engage in costly R&D to bring an innovation to 
market, is central to dynamic efficiency.  Therefore, understanding the degree to 
which innovation benefits consumers versus producers is important for policies 
aimed at trading off the two forms of efficiency, such as intellectual property and 
R&D policies. 
However, empirical evidence on the division of social surplus arising from 
new health care technologies is very scarce or non-existent. To begin to remedy 
this lack of knowledge, this paper investigates this issue for a major breakthrough 
in medicine—the new drugs to treat HIV/AIDS that came on the market after the 
late 1980’s.  HIV/AIDS is an important case to consider in and of itself, partly 
because it is perhaps the major disease targeted by public sector R&D in the US.
2  
For the new HIV drugs that came about during this period, our major finding is 
that innovators captured only 5% of the social surplus arising from these new 
technologies.  More precisely, consumer and producer surplus from these drugs 
amounted to roughly $1.33 trillion and $63 billion, respectively.  We argue that if 
the new HIV/AIDS therapies are representative of other technologies, the lack of 
appropriation of social surplus by innovators has strong policy implications for 
how to adopt and evaluate new health care technologies. Despite the high prices 
of  many  therapies  such  as  the  new  HIV  drugs,  patients  and  health  plans  are 
getting too good a deal in the short run which, of course, hurts them in the long 
run by insufficient R&D.
3 
The low share of appropriation by innovators can be understood by some 
simple back-of-the-envelope calculations.  For the size of the consumer surplus, 
consider the 1.5 million US citizens who have been infected by HIV since the 
start of the epidemic, some of whom died before drug therapy became available 
and some of whom lived until or contracted HIV after the breakthrough drugs 
entered the market in the mid 1990’s.  Averaging across all such cohorts, the gain 
                                                 
2 Public R&D on HIV/AIDS was roughly $2 billion in 2000. Health, in general, is among the three 
leading industries into which the government allocates its R&D, the other two being defense and 
aero-space.  The National Institutes of Health (NIH) is responsible for allocating the vast majority 
of the public R&D dollar—in 1999, NIH funding accounted for nearly 81% of public spending on 
health R&D.  Of the $13.9 billion that the NIH spent on research in 1999, nearly $1.8 billion 
(13%) was spent on HIV/AIDS (Health, United States, 2002). 
3 The inefficiency typically associated with non-appropriation is the classic one discussed in the 
literature.  See, for example, Arrow (1961), Tirole (1988), and more recently, Philipson and Jena 
(2005). in life-expectancy has been at least 5 years.  With a low value of a life-year of 
$100,000,  the  added  survival  has  been  worth  more  than  $500  thousand  per 
individual and $750 billion in aggregate.  This figure, of course, does not include 
the benefit to those individuals who become infected with HIV in later years but 
can  benefit  from  drugs  introduced  to  date—doing  so,  while  assuming  current 
incidence rates persist in the future, raises the total consumer value of these drugs 
above $1 trillion.
4 
For  the  size  of  the  producer  surplus,  consider  that  sales  of  HIV/AIDS 
drugs have grown from $1 billion to $4 billion annually since the breakthrough 
drugs  came  on  the  market  in  1996.  From  these  revenues,  one  can  compute  a 
present value of sales of $74 billion assuming that drugs sell at current levels in 
the  future.    We  can  then  subtract  the  variable  costs  of  production,  which  are 
approximated to be 15% of revenues based on estimates of markups stemming 
from differences in drug prices pre- and post patent expiration. 
This paper is related to several strands of other work. Our finding of a low 
degree of surplus appropriation by innovators of HIV/AIDS drugs relates to an 
existing  literature  outside  of  health  economics  on  the  general  inability  of 
innovators to capture the social value of their inventions.
5  It also relates to a vast 
and growing literature on cost-effectiveness analysis that attempts to assess the 
value  of  new  innovations  mainly  from  the  perspective  of  consumer  surplus, 
wrongly ignoring the incentives for innovation such criteria induce.
6   
The  paper  may  be  briefly  outlined  as  follows.  Section  2  estimates  the 
share of social surplus appropriated by producers for the case of HIV/AIDS drugs.  
Section  3  discusses  how  much  value  is  left  in  future  HIV/AIDS  research  as 
estimated using our methods.  Lastly, section 4 concludes. 




                                                 
4 Our analysis includes future cohorts for several reasons.  First, since the relevant R&D has 
already been undertaken and the subsequent drugs already introduced, it is natural to focus on the 
lifetime returns to innovators (i.e. profits) and the comparable benefits to future infected cohorts.  
In fact, since the vast majority of sales of HIV/AIDS drugs from 1987 to 2000 occurred after 
1995, limiting our analysis to cohorts and firm profits affected to date would lower our estimated 
appropriation.  For example, sales of HIV/AIDS drugs from 1987 to 2000 amounted to $11 
billion, while gross benefits to consumers were roughly $398 billion, implying a surplus 
appropriation of well below 5%. 
5 See e.g., Mansfield et al. (1977), Mansfield (1985), Levin et al. (1987), Hall (1996), and 
Nordhaus (2004). 
6 The literature is vast, but for examples, see Weinstein and Stason (1977), Johanneson  and 
Weinstein (1993), Gold et al. (1996), Meltzer (1997), Drummond et al. (1997), Garber and Phelps 
(1997), Garber (2000), Cutler and McClellan (2001), and Cutler (2004). Section 2: Surplus Appropriation for the New HIV/AIDS Drugs 
 
2.1 Background on HIV/AIDS Drugs 
 
HIV is the causative agent of AIDS (Acquired Immunodeficiency Syndrome), a 
chronic disease characterized by suppression of an individual’s immune system.  
The main mechanism of immune suppression is the destruction of the hosts’ CD4 
(Helper) T-cells—these  cells stimulate the body’s normal immune response to 
bacterial, fungal, and parasitic pathogens.  AIDS can be diagnosed clinically or 
serologically (a low CD4 count).  The clinical manifestation of AIDS includes the 
presence of opportunistic infections (infections that are otherwise harmless to an 
immune-competent individual), AIDS-related cancers, wasting, and dementia.  
The time between initial HIV infection and the onset of AIDS varies, but 
is on average, several years even without treatment.  Much can be done to slow 
this progression and the progression from AIDS to death.  The four classes of 
drugs used to treat HIV/AIDS and the year of first marketing are shown in Table 
1. 
Table 1: HIV/AIDS Anti-retroviral drug classes 
 
Name  Abbreviation  Year of Introduction 
Nucleoside Reverse Transcriptase 
Inhibitors 
NRTI  1987 
Protease Inhibitors  PI  1995 
Non-Nucleoside Reverse Transcriptase 
Inhibitors 
NNRTI  1996 
Fusion Inhibitors  FI  2003 
 
HIV utilizes RNA as its genetic code—upon entry into a cell, the HIV’s own 
machinery (reverse transcriptase) transcribes this RNA into its DNA analog.  This 
transcription process involves building the DNA from a series of small precursors 
called nucleotides.  The NRTIs are essentially ‘fake nucleotides’—they compete 
with the normal nucleotides and when incorporated into the budding DNA chain, 
prematurely terminate transcription.  The NNRTIs do not mimic nucleotides—
instead,  they  directly  bind  to  reverse  transcriptase,  rendering  it  inactive  and 
thereby preventing the formation of DNA. 
  In the absence of any treatment, the DNA produced by the viruses’ reverse 
transcriptase is able to integrate into the host DNA.  That DNA is ultimately used 
by  the  host’s  machinery  to  produce  a  long,  inactive  poly-protein,  a  protein 
comprised of several smaller, active proteins.  It is these smaller proteins that 
enable the newly replicated virus to infect and kill other Helper T-cells.  The PIs 
act by preventing the conversion of the poly-protein into the smaller constituent proteins (this conversion is normally done by the HIV enzyme, protease, hence 
the  name  protease  inhibitor).    The  final  and  most  recently  developed  class of 
drugs,  fusion  inhibitors,  act  by  a  distinct  mechanism—they  prevent  the  initial 
attachment  and  entry  of  HIV  into  the  Helper  T-cell.    Highly  Active  Anti-
Retroviral  Therapy  (HAART)  combines  drugs  from  several  of  the  above 
classes—this combination is more effective in reducing HIV levels in the blood 
and slowing the development of viral resistance.  These drugs are effective in 
lowering viral load and consequently increasing CD4 counts in both AIDS and 
HIV-only patients. 
 
2.2 Valuation Formulas 
 
In this section, we provide the theoretical underpinning for the economic value of 
newly introduced HIV/AIDS drugs.  In short, for a given set of people that are 
diagnosed in a given year, we compare survival rates from HIV/AIDS before and 
after the introduction of Anti-Retroviral (ARV) drugs and attach a monetary value 
to that survival compared to a baseline survival when no drugs were available. We 
repeat  this  for  the  new  set  of  cases,  cohort  by  cohort,  since  the  start  of  the 
epidemic and then aggregate up. 
Since antiretrovirals are effective in slowing the transition from AIDS to 
death  and  from  HIV  to  AIDS,  any  estimates  of  the  value  of  added  survival 
induced by these drugs should not only be restricted to AIDS patients.  Instead, 
these estimates should also account for decreased rates of transition between HIV 
and AIDS.  This suggests that any empirical specification should use survival 
curves conditional on a diagnosis of HIV as opposed to AIDS.  The progression 
from  initial  HIV  infection  to  death  can  be  modeled  in  two  steps  (with  two 
corresponding survival functions):  the transition from HIV to AIDS and from 
AIDS to death.  These  two survival functions can be used to  generate  a new 
survival  function,  St(d),  summarizing  the  transition  from  HIV  to  death  for 
individuals diagnosed with HIV in year t.  This survival curve is assumed to be 
raised by the consumption of new drugs compared to the counterfactual survival 
curve So(d) experienced by those infected in year zero, here taken to be 1979.   
Each year, there is a new cohort of HIV infected people (incidence).   The 
initial cohort of HIV infected people face the survival curve So(d).  The gross 
consumer  surplus,  g,  induced  by  the  new  drug  consumption  is  calculated  by 
multiplying the size of cohort t, nt, by the monetary value of increased survival 











t g n g b     (1) 
 where gt = g(So(d), St(d)), or the monetary value of increasing survival from the 
baseline survival So(d) to the higher future survival faced by cohort t, St(d). 
The  gain  in  survival,  gt,  can  be  calculated  using  the  infra-marginal 
valuation formula of Becker et al. (2005).  They provide the value of survival 
gains for an infra-marginal change in survival from So(d) to St(d) under a yearly 
income  y.    Following  Becker  et  al.  (2005),  this  valuation  is  based  on  the 
willingness of an individual in cohort t (with income yt) to accept a decrease in 
survival from St(d) to So(d).  Formally,  
 
V[yt + et, So(d)] = V[yt, St(d)]   (2) 
 
where V is the indirect lifetime utility function and et is the yearly compensation 
required to make the hypothetical individual indifferent between the two survival 
frontiers.
7  The lifetime value for the gain in survival is calculated by summing 
the yearly compensation (et) over time, discounting by the rate of interest and the 
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This leads to the following expressions for the  yearly  “willingness to accept” 
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where A(S) is the present value of an annuity discounted by the rate of interest 
and the survival probability S.  That is,  
) ( ) (
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b    (6) 
The parametera arises from a utility normalization and is estimated to be -14.97.  
The intertemporal elasticity of substitution (g ) is set to 1.25, and the interest rate 
to 3%.  With the above parameter values and estimates of cohort-specific survival 
curves, we can use the above formulas to estimate the value of gains in survival 
under the willingness-to-accept criterion.   
                                                 
7 Note that the use of yearly, as opposed to lifetime, income (y) and compensation (e) in 
expression 2 follows from the assumption that the discount rate on instantaneous utility equals the 
market rate of discount, i.e. the interest rate.  For more details see Becker, et al. (2005). A major issue in using the above valuation formulas is how the income of 
the target population is determined.  This is particularly relevant to consumers of 
HIV drugs, since they have lower than average incomes.  This is, in part, due to 
an increasing proportion of newly infected individuals who are low-income and 
eligible for Medicaid.  In addition, the disabling nature of the disease often causes 
individuals to leave work, losing both income and employer-sponsored insurance 
(Kates and Wilson, 2004).  Simply using existing estimates of the value of life 
may greatly overstate the value of survival gains from AIDS research if those 
estimated  values  are  based  on  the  average  income  of  the  US  population.    In 
particular,  if  such  estimates  stem  from  wage-mortality  tradeoffs  among  the 
employed  population,  they  may  overstate  value  of  life  estimates  among  the 
unemployed.  Before developing the empirical counterparts of the above valuation 
expressions, we briefly discuss the epidemiology of HIV/AIDS. 
 
2.3 Time Series of HIV/AIDS 
 
Estimating the aggregate value of additional survival for all those diagnosed with 
HIV  requires  data  on  the  incidence  of  HIV  and  cohort-specific  survival 
conditional on the year of diagnosis of HIV (i.e. survival probabilities for cohorts 
diagnosed with HIV in 1984, 1985, etc).  Only within the past ten years have a 
substantial number of states begun mandatory HIV reporting—prior to that, only 
AIDS  cases  were  reported  to  the  Centers  for  Disease  Control  and  Prevention 
(CDC).  This complicates the analysis for two reasons.  First, estimates of HIV 
incidence are not as readily available as those of AIDS incidence.  Second, there 
are  no  published  cohort-specific  survival  curves  with  time  zero  being 
seroconversion (contraction of HIV).  We address these issues, in turn, below. 
Figure 1 graphs AIDS incidence, prevalence, and deaths from the CDC’s 
HIV/AIDS  Annual  Sureveillance  Reports.    Since  early  estimates  of  HIV 
incidence  are  not  available  from  reporting  data  (as  is  the  case  with  AIDS), 
estimates of HIV incidence prior to 1990 were obtained from published figures 
using the method of “back-calculation” (Brookmeyer, 1991).  Since 1990, the 
CDC has estimated incidence to be roughly 40,000 annually—this estimate is 
consistent with data on rates of transmission among hetero- and homo-sexuals and 
prevalence of both groups in the US.
8  There have been over 900,000 diagnosed 
AIDS cases to date, with over 500,000 AIDS related deaths.  There are slightly 
over  400,000  individuals  currently  living  with  AIDS  and  roughly  650,000 
individuals living with HIV only.   
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There are at least three points worth noting in Figure 1.  First, large declines in 
AIDS deaths followed the introduction of Protease Inhibitors and Non-Nucleoside 
Reverse Transcriptase Inhibitors in 1995 and 1996.  Second, there seem to be 
declines in AIDS diagnoses since 1995,  which is consistent with an effect of 
ARVs on the transition from HIV to AIDS.  Finally, the apparent increase in 
AIDS diagnoses around 1993 is, in part, due to a change in the definition of 
AIDS.  Prior to 1993, a diagnosis of AIDS was based on the clinical finding of an 
opportunistic  infection.    After  1993,  the  diagnosis  was  expanded  to  include 
individuals with CD4 counts below 200 per cubic millimeter.  This re-definition 
creates a problem in our construction of AIDS to death survival curves, which we 
address shortly. 
 
2.4 Estimating the Time from AIDS to Death 
 
As noted above, to our knowledge, there are no data available for cohort specific 
survival  curves  for  the  transition  from  HIV  to  death.    To  overcome  this  data 
limitation, we use data from several sources to construct estimates of these curves.  
Using 1) published cohort specific survival curves for AIDS patients (time zero 
being diagnosis of AIDS, as opposed to HIV) for each year from 1984-2000 and 
2) survival curves for transition of HIV to AIDS for 1980-83 and 1996-1997, we construct  survival  curves  for  the  transition  of  HIV  to  AIDS  for  1984-2000.
9  
Under some assumptions, we use our estimated HIV to AIDS and AIDS to death 
survival curves to generate HIV to Death survival curves for each year of HIV 
diagnosis from 1979-2000.
10  It is important to stress that our basic conclusions 
about the returns to HIV/AIDS R&D will not depend on the methods used to 
generate these curves.    
The earlier theoretical  analysis requires the use of survival curves that 
span the entire range of lifetimes.  The survival curves published by the CDC, 
however, are censored five years after diagnosis.  There are two possible ways to 
overcome  this  limitation.    One  way  is  to  fit  the  survival  curves  to  known 
parametric  forms  (such  as  exponential,  Weibull,  or  Gompertz).    This  is 
problematic for several reasons and is considered more carefully in the Appendix.  
The  second  way  to  project  our  survival  curves  forward,  and  the  means  we 
employ,  is  to  assume  that  individuals  who  have  survived  five  years  since  a 
diagnosis of AIDS experience future survival that is typical of, say, a normal 70 
year-old  male.    Intuitively,  individuals  who  have  survived  this  long  still  face 
certain medical problems that lead to lower survival than other normal individuals 
their  age.    However,  they  may  face  survival  probabilities  that  are  similar  to 
individuals  substantially  older  than  them.    While  the  leading  causes  of  death 
differ between the two groups, they do share some similarities—for example, the 
elderly can often die from pneumonia, which is also a common cause of death in 
AIDS patients.  We describe the above estimation procedure more thoroughly and 
examine the robustness of our estimates in the Appendix. 
Figure 2 presents estimated survival curves conditional on a diagnosis of 
AIDS for select years of diagnosis.  AIDS is defined according to the post-93 
definition to ensure comparability across years. 
 
                                                 
9 Survival curves for AIDS patients:  “Survival after AIDS Diagnosis in Adolescents and Adults 
during the Treatment Era,” United States, 1984-1997, Lisa M. Lee, John M. Karon, Richard Selik, 
Joyce Neal, Patricia Fleming, JAMA, March 14, 2001--Vol. 285, No. 10.  The AIDS survival 
curves are generated by following individuals in the official CDC HIV/AIDS Registry over time.  
This differs from the “period life-table” approach to generating survival curves. 
10 Prior to 1993, AIDS was defined by the presence of an opportunistic infection.  After 1993, the 
definition was expanded to include individuals with low CD4 counts (serological diagnosis) as 
well.  Since AIDS patients with opportunistic infections have poorer survival than those diagnosed 
serologically, a comparison of published survival curves for “AIDS” patients in 1984 and 2000 
would overestimate the true increase in survival.  We use data from 1993-1997, for which survival 
information exists under both pre- and post-1993 definitions, to compute an adjustment factor 
which is applied to AIDS survival data from 1984-1992.  This results in estimates of survival from 
AIDS which are comparable over time.  The details are presented in the Appendix. 
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The above figure demonstrates the huge increases in survival experienced by later 
cohorts  diagnosed  with  AIDS  compared  to  their  earlier  counterparts.    In  fact, 
consistent with findings by Goldman et al. (2000) and Bhattacharya and Goldman 
(2003), the  gains in survival arising from the early  HIV/AIDS drugs  (namely 
AZT) were marginal compared to the gains experienced due to the breakthrough 
drugs in the mid 1990’s.  The difference is particularly stark when comparing 
survival among individuals diagnosed with AIDS in 1996 to survival of those 
diagnosed in 1988.  The five year mortality rate is nearly fifty percentage points 
lower in 1996.  Table 2 in the Appendix presents the life-expectancy from AIDS, 
by  year  of  diagnosis.    Our  estimates  suggest  that  life  expectancy  for  AIDS 
patients has increased from 3 years in 1984 to 16.5 years in 2000.   
 
2.5 Estimating the Time from HIV Infection to Death 
 
As stated earlier, the final goal is to arrive at estimates of survival conditional on a 
diagnosis of HIV (not AIDS).   The CDC implemented a program of confidential 
name-based reporting of HIV cases in 1994—this program was adopted by 25 
states.  The CDC has not published official estimates of survival from HIV to 
AIDS using this data.    There are numerous studies in the medical literature, 
however, that follow individuals longitudinally to determine the time from HIV seroconversion to onset of AIDS.  We use data from one such study (CASCADE 
Collaboration), which aggregates data from 38 smaller studies for which the date 
of seroconversion can be reliably estimated.  Specifically, we use data on AIDS-
free survival of HIV infected individuals in two periods, 1980-83 and 1996-97.
11  
For  each  of  the  two  time  periods,  we  have  a  single  survival  curve.    The 
individuals in this study are drawn from Europe, Australia, and North America 
and consequently may not be fully representative of the HIV infected population 
in the US.  However, comparisons with other estimates within the US show little 
difference. 
With estimated AIDS-free survival curves for individuals infected with 
HIV  in  1980-83  and  1996-1997  in  hand,  we  estimate  survival  for  each  year 
between these two time periods using the following strategy.  We assume that 
survival in each year from 1979 to 1983 is equivalent to the survival estimated for 
the four year period as a whole.  Similarly, we assume that the AIDS-free survival 
for each year from 1997 to 2000 is equivalent to the estimated survival for 1996-
1997.    Using  these  two  sets  of  survival  curves  as  bounds  for  survival  in  the 
intermediate years, we assume that survival in the intermediate years evolves in a 
manner similar to the survival from AIDS to death during those same years, on 
which we have estimates.  Specifically, we assume that the share of the total 
increase in HIV to AIDS survival from 1980-2000 that occurs between 1984 and 
1985 is equal to the share of total improvement in AIDS survival that takes place 
between those same years.  This implicitly assumes that between years, treatment 
affects the transition from HIV to AIDS and AIDS to death relatively the same, 
the frame of reference being the total improvement in survival for each group 
from 1980-2000. 
Using the previously estimated survival curves for AIDS and the AIDS-
free  survival  for  HIV  infected  individuals,  we  generate  survival  curves 
conditional on an infection with HIV for each year from 1979 to 2000.  The 
details behind this estimation are presented in the Appendix.  Figure 3 presents 
the survival after an infection with HIV, by year of infection.  Table 3 in the 
Appendix presents the average time to onset of AIDS and the life-expectancy 
after HIV infection for various years of HIV infection.   
 
                                                 
11 The AIDS-free survival in the CASCADE study is censored at 13 years.   We fit the remainder 
of each survival curve using the Weibull specification.  The fact the published survival curves 
extend 13 years allows us to reliably do so. 
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From the above graph and Table 3 in the Appendix, it is clear that advances in 
treatment have led to increases in both the time to onset of AIDS and the period of 
time  alive  after  a  diagnosis  of  AIDS.    The  life-expectancy  of  the  average 
individual infected with HIV has increased roughly 15 years since the start of the 
epidemic, from 19 to 34 years.  These figures are slightly larger than those in the 
literature—for example, the mean incubation time of HIV (time  from  HIV to 
AIDS) in the early 1980’s is generally thought to be between 10 and 11 years, 
while the life-expectancy after AIDS is 3 - 4 years.  These estimates suggest an 
initial life-expectancy from HIV of almost 15 years, so our above estimates are 
not far off.   
  To  further  verify  the  reasonableness  of  our  estimates,  we  can  use  our 
estimated annual HIV survival curves and reported data on annual HIV incidence 
to estimate the current number of individuals infected with HIV/AIDS.  We can 
then  compare  this  imputed  figure  to  published  figures  from  the  CDC.  
Specifically, we multiply the incidence of HIV in a given year by the proportion 
of  individuals  infected  with  HIV  in  that  year  who  survive  until  2003,  as 
determined from the estimated survivals.  Doing so from the very beginning of the 
epidemic, we estimate 1,055,097 to be living with HIV/AIDS in 2003.  This can 
be  compared  to  the  CDC  estimate  of  1,067,522,  a  difference  of  only  12,424 
people!  It is important to note that these differences will not impact the sheer magnitude of the value of gains in survival.
12  With estimated survival for various 
cohorts infected with HIV in hand, we now turn to valuing the gains in survival.  
 
2.6 Valuing the Gains in Survival due to HIV/AIDS Drugs 
 
Using survival of an individual infected with HIV in 1979 as a benchmark, we use 
the  valuation  formulas  described  earlier  to  compute  the  lifetime  value  to  an 
individual of increasing survival to that of someone infected with HIV in a given 
later  year.    Aggregate  values  for  each  year  are  computed  by  multiplying  that 
year’s  incidence  of  HIV  by  the  value  of  increased  survival  experienced  by  a 
single individual in that cohort.  Note that these figures ignore the behavioral 
change that raises incidence in response to better treatments, which we discuss 
more fully in the Conclusion.  The income used in the calculations is GDP per 





















                                                 
12  The calculated survival functions suggest an upper bound of the increase in life-expectancy 
attributable to HIV/AIDS drugs.  This is due to concomitant advances in the treatment of 
HIV/AIDS in areas other than anti-retrovirals.  From 1984 to 2000, life expectancy increased by 
nearly fifteen years for individuals infected with HIV and thirteen years for individuals diagnosed 
with AIDS.  This can be compared to the estimates of Lichtenberg (2005), who estimates increases 
in AIDS life-expectancy of nearly 22 years from 1993 to 2001, 13 years of which is attributable to 
HIV/AIDS drugs. 
 Table 2: Value of Gains in Survival for HIV Infected Individuals 
 










1980  20,000  17,655  0.35 
1981  58,000  39,361  2.28 
1982  100,000  60,256  6.03 
1983  130,000  84,941  11.04 
1984  160,000  116,156  18.59 
1985  160,000  146,874  23.50 
1986  140,000  178,968  25.06 
1987  120,000  214,389  25.73 
1988  80,000  250,284  20.02 
1989  50,000  287,924  14.40 
1990  40,000  322,311  12.89 
1991  40,000  339,957  13.60 
1992  40,000  383,328  15.33 
1993  40,000  432,908  17.32 
1994  40,000  567,422  22.70 
1995  40,000  613,839  24.55 
1996  40,000  696,951  27.88 
1997  40,000  718,603  28.74 
1998  40,000  730,179  29.21 
1999  40,000  738,839  29.55 
2000  40,000  740,515  29.62 
Total Discounted Value  398 
All figures are discounted to 1980 and are in year 2000 dollars. 
 
The  above  results  suggest  that  the  aggregate  value  of  improved  survival 
experienced by all individuals infected with HIV to date has been nearly $400 
billion.  This, of course, ignores the value of increasing survival for all individuals 
who have not contracted HIV  yet, but will do so in the future.  We add this 
component to our calculations later in the section. 
We can compare our value of life estimates with other estimates in the 
literature. One way of doing this is by calculating the gain in life-expectancy 
induced by our estimated survival functions and then using existing estimates of 
the value of a life-year to value the changes in life-expectancy induced by HIV 
drug consumption.  Since life-expectancy associated with a survival curve is its sum over ages, if we have an estimate of the value of a life-year, v, the value of 
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This implicitly assumes an age-invariant value of a life-year, but adjusting this 
value for age may, of course, also be done.  Using common estimates of the value 
of a life-year in the range of $100 thousand (Cutler and Richardson, 1998), we 
can calculate the value of increasing life expectancy from the benchmark to that 
of a cohort diagnosed in a given year.  Table 3 presents the value of the gain in 
life expectancy based on the value of a life-year equal to $100,000.  Note that 
when calculating the value of increased life expectancy using the value of a life-


























 Table 3: Comparing the value of life to estimates in the literature 
 













Value of Gain 
in Life 
Expectancy 
Using Value of 
a Life-Year 
($) 
1980  17,655  0.6  60,000 
1981  39,361  1.2  116,505 
1982  60,256  1.9  179,093 
1983  84,941  2.6  237,937 
1984  116,156  3.2  284,316 
1985  146,874  3.9  336,418 
1986  178,968  4.6  385,243 
1987  214,389  5.3  430,939 
1988  250,284  5.9  465,752 
1989  287,924  6.6  505,835 
1990  322,311  7.3  543,189 
1991  339,957  7.8  563,489 
1992  383,328  8.7  610,201 
1993  432,908  9.7  660,523 
1994  567,422  12.4  819,786 
1995  613,839  13.3  853,677 
1996  696,951  14.8  922,287 
1997  718,603  15.0  907,525 
1998  730,179  15.1  886,966 
1999  738,839  15.1  861,132 
2000  740,515  15.1  836,051 
All figures are discounted to 1980 and are in year 2000 dollars. 
 
For recent years, the value of increased life expectancy derived from the value of 
a life-year is similar to our value of life estimates, amounting to nearly $750 
thousand for year 2000 survival. 
As alluded to earlier, the consumer benefit from HIV/AIDS drugs does not 
simply include the aggregate value calculated to date, but also includes the value 
to  future  cohorts  of  increased  survival.    We  can  forecast  the  value  to  future 
cohorts of HIV infected individuals by assuming that all cohorts experience the 
same aggregate gain in survival gt as the last cohort, 2000.  Hence, we assume 
0 2000 2000 > " = + t g g t     (8) Assuming that the future incidence of HIV is equivalent to the last period, we can 
calculate the discounted sum of future gains for individuals infected with HIV in 
the  future.    We  then  add  this  amount  to  the  value  to  date  calculated  earlier, 
namely $398 billion.   This leads to an aggregate value of increased survival for 
all past and future cohorts of nearly $1.4 trillion.  In the next section, we calculate 
the lifetime profits and variable costs associated with production.  This allows us 
to decompose the total value of HIV/AIDS drugs into consumer surplus, producer 
surplus (profits), and costs. 
 
2.7 Dividing the Social Surplus into Producer and Consumer Surplus 
 
The overall producer surplus obtained from R&D is determined by the present 









t p b p   (9) 
An upper bound of producer surplus is the aggregate sales for HIV/AIDS drugs.  
An alternative lower estimate takes out variable costs.  We do this by applying 
existing  estimates  of  markups  for  brand-name  drugs  estimated  from  patent 
expirations, and applying those markups to the observed aggregate sales. 
Figure  4  presents  estimates  of  national  spending  on  HIV/AIDS  drugs 
broken down by public and private payers.  The estimates for total spending are 
from IMS Health and are reported in Lichtenberg (2005).  Public spending is 
approximated by the sum of Medicaid and ADAP expenditures.  The Medicaid 
estimates include both federal and state contributions and were calculated from 
the Medicaid State Drug Utilization Data using National Drug Codes (NDC) for 
all antiretrovirals introduced since 1987.
13   Medicaid expenditure on HIV/AIDS 
drugs  is  unavailable  prior  to  the  last  quarter  of  1991—this  is  likely  because 
Medicaid  began  its  Prescription  Drug  Rebate  Program  (for  all  drugs,  not  just 
ARVs)  only  in  1990.
14   Data  on  ADAP  expenditures  are  unavailable  prior to 
1996,  though  it  was  informally  covering  some  individuals  through  the  Ryan 
White CARE Program prior to that.
15 
                                                 
13 http://www.cms.hhs.gov/medicaid/drugs/drug5.asp 
14 See “Key Milestones in CMS Programs” for more detailed information: 
http://www.cms.hhs.gov/about/history/milestones.asp 


























Figure 4 demonstrates the large increase in spending on HIV/AIDS drugs in the 
past ten years.  Since 1995, spending has increased from $250 million to almost 
$4 billion, largely due to increased spending on protease inhibitors and nucleoside 
reverse  transcriptase  inhibitors.    Figure  5  also  depicts  the  large  share  of  total 
spending on HIV/AIDS drugs that comes from public sources, nearly 50% from 
1997 onwards. 
In order to estimate the aggregate lifetime profits from HIV/AIDS drugs, 
we must make assumptions about future sales.   One possibility is to assume that 
future sales are equal to last-period sales, in this case national sales of HIV/AIDS 
drugs in 2000.  We use estimates from the literature on the prices of generic drugs 
relative to their branded counterparts to assume variable costs to be no more than 
15% of sales (Caves, et al., 1991).
16  With sales in the future being equivalent to 
year 2000’s patent-protected sales, we estimate lifetime sales to be roughly $74 
billion.  This suggests a lifetime variable cost of production of $11.1 billion (74 x 
0.15) and lifetime profits of $62.9 billion. 
Using the above figures, we can decompose the total lifetime value of 
HIV/AIDS  drugs  into  consumer  surplus,  producer  surplus  (profits),  and 
                                                 
16 In “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry,” R. Caves, 
M. Whinston, and M. Hurwitz estimate that with 20 generic competitors, the ratio of prices 
between generic and brand drugs is roughly 17%.  We use the price of generic drugs as an upper 
bound of the marginal costs of production. production  costs.    Recall  that  we  estimated  the  total  value  to  be  nearly  $1.4 
trillion,  discounted  to  1980  in  year  2000  dollars.    This  amounts to  a  lifetime 
consumer surplus of roughly $1.33 trillion ($1.4 trillion – $74 billion).  With a 
social surplus (total value net of production costs) of $1.38 trillion, almost 95% is 
captured in the form of consumer surplus.   
 
Section 3:  Potential Gains from Future R&D 
 
The  previous  analysis  of  the  value  of  life  gains  induced  by  HIV/AIDS  drugs 
introduced to date suggested a gross benefit to consumers of nearly $1.4 trillion.  
This begs the question:  In the current environment in which several HIV/AIDS 
drugs already exist, what is the added value of a complete cure for AIDS?  Figure 
5 below illustrates this question.   
 

























1980 HIV 2000 HIV 2000 Normal
 
As demonstrated  earlier, the survival  for  an individual infected  with HIV has 
improved dramatically since 1980.  Also plotted in Figure 5 is the survival of a 
normal, healthy 30 year-old individual in 2000—the area between the survival of 
an individual infected with HIV in 2000 and that of a healthy individual in the 
same year represents the gain in life-expectancy for the HIV-infected individual 
from a cure for AIDS.  The added value from a cure for AIDS is divided among two groups, those individuals who have contracted HIV in the past and can now 
resume normal, healthy lives and those individuals who contract HIV in the future 
and would otherwise experience survival typical of someone infected with HIV in 
2000.   
We can use the previously described methodology to estimate the added 
value from a cure for AIDS.  Supposing a complete cure becomes available in 
2010, we can modify our survival curves to account for a complete cure that 
restores survival to that of normal individuals.
17  For example, these modifications 
take into account that an individual who survives to 2010 after contracting HIV at 
the age of 30 in 1990 follows survival of a healthy 50 year-old after being cured 
of HIV/AIDS.  Essentially replicating our earlier analysis, we estimate the value 
to  increased  survival  induced  by  both  drugs  introduced  to  date  and  a  cure 
introduced in 2010 to be nearly $3.2 trillion.  Recall that the value of life induced 
by  drugs  introduced  to  date  (with  no  cure)  was  estimated  to  be  roughly  $1.4 
trillion.  This suggests that there is almost $1.8 trillion of gross benefit to be had 
from a complete cure for AIDS.  This raises the question of whether producers 
should be appropriated more surplus to close the remaining gap in HIV/AIDS 
survival. 
 
Section 4:  Conclusion 
 
The  value  of  an  innovation  may  be  divided  into  the  gains  to  consumers  and 
innovators. We estimated that for the HIV/AIDS therapies that entered the market 
from  the  late  1980’s  onwards,  innovators  appropriated  only  5%  of  the  social 
surplus arising from these new technologies.   
Despite the high prices of these drugs to patients and health plans, the low 
share of social surplus going to innovators raises concerns about advocating cost-
effectiveness  criteria  that  would  further  reduce  this  share,  and  hence  further 
reduce  incentives  for  innovation.  In  particular,  popular  technology  assessment 
criteria  in  healthcare  going  under  the  rubric  of  “cost-effectiveness”  often 
implicitly maximize consumer surplus, which is consistent with maximizing static 
efficiency after an innovation has been developed.  Dynamic efficiency, however, 
aligns the social costs and benefits of R&D and is therefore determined by how 
much of the social surplus from a new technology is appropriated by producers.  
Our findings suggest several questions to be addressed by future research. 
First, why is the share of surplus appropriated by producers so small and the cost-
effectiveness so seemingly high?  One may be tempted to argue that there is a 
lack of market power of those holding patents on these new technologies due to 
therapeutic competition within drug classes.  However, this certainly does not 
                                                 
17 Recall that these survival curves already account for improved survival due to drugs introduced 
to date. seem to be the case for the breakthrough drugs in HIV/AIDS.  Furthermore, in a 
related  theoretical  analysis,  Philipson  and  Jena  (2005)  show  that  even  if 
substitutes do not exist and patents are very broad, as when demand is highly 
inelastic, the share of the social surplus allocated to the producer may be very 
small.     
Second,  the  small  estimated  share  of  social  surplus  appropriated  by 
investors  sheds  important  light  on  the  recent  growth  of  alternative  funding 
mechanisms to stimulate HIV/AIDS research, e.g. through advance purchasing 
contracts of governments or private foundations.
18  Given that there is a social 
surplus above a trillion that is not appropriated by R&D investors, a few billion 
dollars added to stimulate innovation, as these public or private contracts seem to 
provide,  seems  to  pale  in  comparison  to  the  missed  consumer  surplus  not 
appropriated. 
Third, the economic epidemiology of chronic infectious diseases may alter 
the  social  value  of  HIV/AIDS  drugs  (Philipson,  2000).    For  example,  one 
behavioral response to treatment may be an increase in incidence due to a lower 
cost of risky behavior.  This might be mitigated by the longer life-expectancies 
(and  prolonged  ability  to  infect  others)  of  HIV  infected  individuals  receiving 
treatment.    Offsetting  this  second  effect,  however,  is  the  fact  that  current 
treatments lower the viral load and reduce the probability of infection at any point 
in time.  While these external effects may alter the social value of HIV/AIDS 
drugs, their effect on the private value, which we consider here and is the target of 
producer appropriation efforts, is likely limited. 
Finally, the peculiar aspects of healthcare markets may raise some non-
standard issues regarding the efficient form of surplus appropriation.  One issue 
concerns  the  effect  of  altruism,  which  seemingly  motivates  much  of  public 
financing, on optimal technology adoption.
19  A second concerns the effect of ex-
post inefficiencies such as moral hazard.  A third concerns the impact of the joint 
demand of physicians and patients as would be the case of the pharmaceutical 
industry considered here. 
Our  analysis  and  evidence,  if  they  generalize  to  other  technologies, 
suggest that interventions should be sought to attempt to raise producer surplus 
levels for new technologies. Even though this would lead to lower observed levels 
of cost-effectiveness for these technologies, dynamic efficiency would be raised.  
 
 
                                                 
18 See e.g. The Center for Global Development (2005) and the efforts undertaken by The Gates 
Foundation (2005). 
19 Philipson and Mechoulan (2003) discuss optimal technology assessment in the presence of 
altruism that motivates public healthcare delivery, in general, and R&D into third-world diseases, 
in particular. Appendix 
 





OI N and 
t
S N be the shares of newly diagnosed AIDS cases in year t based on 
opportunistic infection (OI) and CD4 count (S), respectively.  They sum to one.  
Let  ) (d S
t
OI and  ) (d S
t
S be the corresponding survival curves.  Under the pre-1993 
definition, a diagnosis of AIDS includes only those individuals with an OI.  Under 
this definition, the proportion alive after d periods is: 




PRE =  
 Under the post-1993 definition, a diagnosis of AIDS includes those with an OI 
and those with a low CD4 count.  The proportion alive after d periods under the 
post-1993 definition is, 
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a  weighted  average  of  the  two  survival  functions.    Note  that  ) (d A
t
POST  is  the 
survival curve conditional on a diagnosis of AIDS used by the CDC after 1993.  
For 1993-1997, we have survival curves conditional on a diagnosis of AIDS for 





POST  for t=1993-1997.  Subtracting the two curves, we obtain, 
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We can rewrite this as  










POST + - × = . 
This expression suggests two ways of estimating  ) (d A
t
POST for years prior to 1993 
using survival curves available for those years, namely ) (d A
t
PRE .   
Case 1: 






S - ×  for t=1993-1997, and 
add this correction factor to  ) (d A
t
PRE for years before 1993.  Instead of averaging, 
we might alternatively apply )) ( ) ( ( ) (
1993 1993 1993 d S d S d N OI S S - × to all previous years. 
 
 
 Case 2: 
Second, since ) (d A
t
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OI , and  ) (d N
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S are known for 1993-1997, 
we can use these to back-calculate  ) (d S
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S are not known for years prior to 1993, we might use 1993 values for all 
calculations.  That is,  
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POST + - × =  for t<1993. 
Given that the true correction factor for  ) (d A
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S - × , we 
can compare this to the two cases above.  For notational convenience, let t=1993 
and for Case 1, consider  )) ( ) ( ( ) (
1993 1993 1993 d S d S d N OI S S - × as opposed to the average.  
Consider  Case  2  first.    The  true  correction  factor 
)) ( ) ( ( ) (
1984 1984 1984 d S d S d N OI S S - × will be less than the correction factor in Case 2, 
)) ( ) ( ( ) (
1984 1993 1993 d S d S d N OI S S - × ,  since  ) ( ) (
1984 1993 d S d S S S > and 
) ( ) (
1984 1993 d N d N S S > .  The latter is true since a greater share of newly diagnosed 
AIDS cases are likely to be only serologically diagnosed in the later years due to 
better drug therapy.  Thus, the correction factor for Case 2 would be an upper 
bound of the true correction factor—estimated survival curves would overstate the 
true  survival  curves.    Reversely,  )) ( ) ( ( ) (
1984 1984 1984 d S d S d N OI S S - × is  likely  to  be 
closer to  )) ( ) ( ( ) (
1993 1993 1993 d S d S d N OI S S - × , the correction factor for Case 1.  This is 
because  the  effects  of  ) (
1993 d NS and  ) (
1993 d SS are  in  part  mitigated  by  the  fact 
that ) ( ) (
1984 1993 d S d S OI OI > , which brings correction factor 1 closer towards the true 






                                                 
20 One might alternatively consider a multiplicative adjustment factor in which  ) (d A
t
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this for two reasons.  First, the theoretical relationship between  ) (d A
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PRE ] that are low for early years (since the base by which the adjustment factor is multiplied 
is smaller).  This is inconsistent with the data, which demonstrates that, for the years available, 
this difference is roughly independent of the level of survival. Estimating Survival from AIDS 
 
Parametric  estimation  of  AIDS  survival  curves  published  by  the  CDC  is 
problematic for several reasons.  First, the exponential distribution has a constant 
hazard,  which  is  rejected  in  our  data—in  our  case,  the  non-parametric  plots 
exhibit  a  declining  hazard.    Second,  the  Gompertz  specification,  which  is 
commonly used to characterize normal life tables, is inconsistent with the survival 
patterns seen in AIDS patients.  Third, since survival curves after the mid-90’s 
exhibit almost 50% survival in the first five years, out-of-sample predictions of 
future survival are unreliable.  For example, fitting the 1995 survival curve to the 
Gompertz  specification  results  in  nearly  50%  of  individuals  still  alive  10,000 
months after diagnosis of AIDS—similar results hold for the Weibull.  Note that 
is not a problem with earlier years.  For example, fitting the 1984 survival curve 
to the Weibull distribution results in nearly all individuals dead within 20 years of 
diagnosis.  This is due to the fact that, unlike survival in later years, only 20% of 
individuals survive past five years of diagnosis. 
Another  way  to  project  our  survival  curves  forward  is  to  assume  that 
conditional on surviving five  years  after a diagnosis of AIDS, future survival 
follows the survival of a normal individual conditional on reaching age Y, where 
Y is determined by the following expression, 
 
SAIDS(d|Surviving 5 years since diagnosis in year t) = S(d|Y years old in year t+5) 
 
The value of Y should differ across diagnosis cohorts.  That is, an individual who 
is alive in 1990 after being diagnosed with AIDS five years earlier will certainly 
face different survival prospects than an analogous individual ten years later.  Our 
intuition for generating values of Y is the following.  Individuals diagnosed with 
AIDS in 1984 experienced a death rate of nearly 75% within the first five years.  
We can use survival curves for normal individuals in 1984 to determine which 
age group X experienced a similar death rate over the course of five years.  We 
can then use the survival curve of Y year-olds in 1989 (where Y = X + 5) to 
project the 1984 AIDS survival curve past five years of diagnosis.  Again, the idea 
behind this method is that normal elderly individuals who face similar prospects 
for five-year survival as do younger AIDS patients may also face similar survival 
rates later on.     
In the actual estimation, we restrict our attention to changes in survival 
within the last year of the five-year period.  Specifically, instead of considering 
the rate of death over the five-year period after diagnosis, we consider the rate of 
death  between  years  four  and  five.    We  then  determine  the  ages  of  normal individuals with similar one-year death rates.
21  The estimated ‘AIDS survival 
equivalent ages’ are presented in Appendix Table 1.  Figure 1 in this Appendix 
compares  projected  survival  curves  generated  by  the  parameterization  and 
imputation methods.  For the years in which both methods were used, 1984-1993, 
the estimated survival curves are quite similar.   
 
Table 1: Age of Normal Cohort Whose 1-Year Death Rate is Equivalent to AIDS 
Death Rate between Years 4 and 5 Post-Diagnosis 
 
Year of AIDS 
Diagnosis 
Age 
1984  86 
1985  86 
1986  86 
1987  86 
1988  87 
1989  87 
1990  85 
1991  84 
1992  81 
1993  78 
1994  73 
1995  73 
1996  73 
1997  73 
1998  72 
1999  68 
2000  68 
                                                 
21 Since individuals comprising the latter part of the AIDS survival curve might differ 
systematically from those on the early part, we focus on the latter part when generating our 
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Table 2 presents estimates of life expectancy conditional on a diagnosis of AIDS 
in a given year.  Our estimates suggest that life expectancy has increased from 2.9 
years in 1984 to 16.5 years in 2000.   
 
Table 2: Life Expectancy after a Diagnosis of AIDS for Various Years of 
Diagnosis 
 
Year  Life expectancy 
conditional on AIDS 
Diagnosis 
1985  2.9 
1988  3.6 
1991  4.3 
1994  9.5 
1997  13.0 
1998  13.7 
1999  16.1 
2000  16.5 
 
These  estimates  differ  somewhat  from  others  in  the  literature.    For 
example, Lichtenberg estimates life expectancy of an individual diagnosed with AIDS in 1993 (2000) to be 3.7 (26.3) years.  This might, in part, be due to his 
period life-table rather than cohort specific approach.  In addition, he assumes a 
constant hazard (mortality rate)—the calculated life expectancy is equal to the 
inverse of the hazard.  A comparison of our year 2000 survival curve with that of 
Lichtenberg (exponential distribution with hazard =.038) demonstrates that the 
two track each other fairly closely for the first 20 years.  After that, however, our 
survival falls off much more rapidly—for example, 30 years after diagnosis, 32% 
(as opposed to 11%) are still alive in the exponential specification.
22 
To further check the robustness of our results, we use a slightly different 
specification  to  project  the  AIDS  survival  curves.    Specifically,  an  individual 
diagnosed with AIDS in 1995 who is still alive 5 years later may expect a survival 
similar to individuals diagnosed with AIDS in 2000.  Similarly, an individual 
diagnosed with AIDS in 1984 who is alive in 1989 may expect survival similar to 
an individual of the same age diagnosed in 1989.  Fixing the 2000 survival curve 
to  the  one  calculated  before,  we  can  “back-calculate”  survival  curves  for 
individuals diagnosed in earlier years according to the above algorithm.   The life 
expectancies generated by the ‘back-calculation’ method are on average 2.2 years 
longer, with the majority of the differences lying in the later years.  Since the 
magnitude of our results does not depend crucially on this difference, we use the 
survival curves generated by the imputation method in all subsequent analysis. 
 
Generating Survival Conditional on an Infection with HIV 
 
We use discrete-time AIDS-free survival SHIV(d) for an HIV infected individual to 
obtain the probability distribution function, fHIV(d).  This distribution states the 
proportion of individuals who contract AIDS exactly d years after HIV infection.  
This  distribution  is  allowed  to  vary  by  year  of  HIV  infection  to  capture  the 
delayed  progression  to  AIDS  due  to  antiretroviral  treatment.      Consider  an 
individual infected with HIV in 1979.  With probability fHIV,79(1), this individual 
contracts AIDS within the next year and faces the survival curve for an individual 
diagnosed  with  AIDS  in  1980.    Similarly,  with  probability  fHIV,79(2),  this 
individual contracts AIDS exactly two years after infection with HIV and faces 
                                                 
22 To compare the reasonableness of our end-of-life assumptions, we make the following 
calculation.  Suppose that the life expectancy of an individual diagnosed with AIDS in 2000 is, in 
fact, 26.3 years.  Using CDC data on the first 5 years of survival, we can project survival past 5 
years using the survival curve of a normal individual of age Y.  The question we ask is—what age 
Y is consistent with an overall AIDS life expectancy of 26.3 years?  The answer is Y = 51 years.  
Thus, conditional on being alive five years after a diagnosis of AIDS, instead of assuming the 
survival of a normal 45 year-old, an AIDS patient assumes the survival of a normal 51 year-old.  
This implies that for these individuals, AIDS lowers life expectancy by only 4.5 years, which 
seems too low. the survival curve for an individual diagnosed with AIDS in 1981.  Using this 
logic, the survival curve for an individual infected with HIV in 1979 is 
￿ + - × + - × = ) 2 ( ) 1 ( ) 1 ( ) 1 ( ) (
1981 1980 1980 1979 1979 d S f d S f d S AIDS HIV AIDS HIV HIV  
which is a weighted average of the survival from AIDS for different years of 
AIDS diagnosis.  Note that the lags in the survival functions account for the fact 
that the individual has lived several years before contracting AIDS.  For years 
after 2000, we assume that the survival curve for AIDS takes its 2000 value.  We 
use the above metric to generate estimates of survival conditional on an infection 
with HIV for each year from 1979 to 2000.  These are presented in Table 3 below. 
 
Table 3: Average Time to Onset of AIDS and Life Expectancy after an Infection 







1980  13.3  19.6 
1983  13.3  21.6 
1986  13.3  23.6 
1989  13.4  25.6 
1992  14.4  27.7 
1995  21.5  32.3 
1998  23.9  33.2 
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